CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 154 enrolled
Drug / intervention
Semaglutide, 1.34 mg/mL +1 moredrug
Likely dose
Semaglutide, 1.34 mg/mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05193578
NCT05193578Phase 2Completed
CompareCT.gov

Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

Jan Frystyk·interventional·Posted Jan 18, 2022·Updated Jul 8, 2024

In Brief

A Phase 2 clinical trial evaluating Semaglutide, 1.34 mg/mL and Placebo for Schizophrenia and Prediabetic State. Completed, enrolled 154 participants across 1 site.

Detailed Summary

To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome in people with pre-diabetes, overweight and schizophrenia, who receive antipsychotic treatment. Furthermore to investigate for an effect of Semaglutide compared to placebo on psychotic symptoms and quality of life in people with schizophrenia, prediabetes and overweight.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Prediabetic State
CountriesDenmark
CollaboratorsRegion Zealand, Region of Southern Denmark, Steno Diabetes Center Sjaelland, Steno Diabetes Center Odense

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJan 18, 2022
Enrollment StartJan 1, 2022
Primary CompletionMar 18, 2024
Study CompletionMay 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.5 years ago

Interventions

Semaglutide, 1.34 mg/mLdrug

Semaglutide, 1.34 mg/mL

Placeboother

Semaglutide-Placebo